Alpa.Kl
ALPA.KL operates in the Advanced Medical Equipment & Technology industry, providing healthcare services and equipment, primarily generating revenue through the sale and provision of medical technologies and related services.
Business. ALPA.KL operates in the Advanced Medical Equipment & Technology industry, providing healthcare services and equipment, primarily generating revenue through the sale and provision of medical technologies and related services.
Analyst recommendations
2 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
ALPA.KL operates in the Advanced Medical Equipment & Technology industry, providing healthcare services and equipment, primarily generating revenue through the sale and provision of medical technologies and related services.
ALPA.KL maintains a strong capital structure with a debt-to-equity ratio of 0.12, indicating a low reliance on debt financing. The company's liquidity position is characterized by a current ratio of 7.29, suggesting a robust ability to meet short-term obligations. However, the company's net cash position is negative after subtracting total debt, which introduces a medium liquidity risk.
Profitability metrics for ALPA.KL are strong, with a return on equity (ROE) of 29.01% and a return on assets (ROA) of 22.91%. These figures exceed the typical performance benchmarks for the Advanced Medical Equipment & Technology industry, indicating efficient use of equity and assets to generate returns.
The company's revenue is primarily concentrated in the domestic market, with no significant geographic diversification disclosed. While this may offer operational simplicity, it also exposes the company to regional economic fluctuations. No specific segment breakdown is available, but the company's primary business activity is centered on advanced medical equipment and technology.
ALPA.KL's growth trajectory is positive, with a strong operating cash flow of MYR 55,267,030 and a free cash flow of MYR 10,374,520. The company's capital expenditure of MYR -7,809,130 suggests a focus on maintaining rather than expanding its asset base. Analysts have assigned a mean price target of MYR 0.35, with a mean recommendation of 1.50, indicating a generally positive outlook.
The company faces a medium liquidity risk, primarily due to its negative net cash position after accounting for total debt. Dilution risk is assessed as low, with no significant dilution potential identified in the basic shares outstanding. No recent dilutive events or adjustments have been applied to the valuation metrics.
Recent events and filings do not indicate any major operational or financial disruptions. The company's financial performance remains stable, with no significant changes in its business model or strategic direction reported in the latest available data.
- ALPA.KL has a strong profitability profile with ROE and ROA significantly above industry norms.
- The company's liquidity position is robust, with a high current ratio, but its net cash position is negative after subtracting total debt.
- ALPA.KL's revenue is primarily concentrated in the domestic market, which may limit its exposure to global growth opportunities.
- Analysts have a generally positive outlook, with a mean price target of MYR 0.35 and a mean recommendation of 1.50.
- The company's capital structure is conservative, with a low debt-to-equity ratio and minimal dilution risk.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | 0,01 |
| Revenue | —no estimate | —no estimate | 204,0M MYR |
| Operating income | —no estimate | —no estimate | 69,0M MYR |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- ALPA.KL Market data — financials · 2026-05-27
- Alpha IVF Group Bhd Market data — analyst estimates · 2026-05-27